A new research document with title ‘Amyloidosis – Pipeline Review, H2 2017’ covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis and important players/vendors such as Bsim2, Celgene Corp, GlaxoSmithKline Plc etc. The report will help user gain market insights, future trends and growth prospects for forecast.
Request a sample report @ https://www.htfmarketreport.com/sample-report/593309-amyloidosis-pipeline-review-1
Amyloidosis – Pipeline Review, H2 2017
The latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis – Pipeline Review, H2 2017, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape.
Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of abnormal protein called the light chain and its subsequent deposition in the body. It may also occur as a result of dialysis. Symptoms include fatigue, chest pain, swelling and breathing problems. Amyloidosis can be managed by transplant and, medication such as diuretics and chemotherapy drugs.
The Pharmaceutical and Healthcare latest pipeline guide Amyloidosis – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Amyloidosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Amyloidosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 7, 7, 6 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.
Amyloidosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Amyloidosis (Metabolic Disorders).
– The pipeline guide reviews pipeline therapeutics for Amyloidosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Amyloidosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Amyloidosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Amyloidosis (Metabolic Disorders)
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=593309
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Amyloidosis (Metabolic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Amyloidosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Alnylam Pharmaceuticals Inc
Arcturus Therapeutics Inc
Ionis Pharmaceuticals Inc
Johnson & Johnson
Millennium Pharmaceuticals Inc
Neurimmune Holding AG
Prothena Corp Plc
Regeneron Pharmaceuticals Inc
SOM Biotech SL
Spectrum Pharmaceuticals Inc
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/593309-amyloidosis-pipeline-review-1
Table of Contents
List of Tables 4
List of Figures 4
Global Markets Direct Report Coverage 5
Amyloidosis – Overview 6
Amyloidosis – Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Amyloidosis – Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Amyloidosis – Companies Involved in Therapeutics Development 23
Alnylam Pharmaceuticals Inc 23
Amgen Inc 23
Arcturus Therapeutics Inc 24
Celgene Corp 25
GlaxoSmithKline Plc 25
Ionis Pharmaceuticals Inc 26
Johnson & Johnson 26
Millennium Pharmaceuticals Inc 27
Neurimmune Holding AG 27
Novartis AG 28
Oncopeptides AB 28
Pfizer Inc 29
Prothena Corp Plc 29
R Pharm 30
Regeneron Pharmaceuticals Inc 30
SOM Biotech SL 31
Spectrum Pharmaceuticals Inc 31
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/593309-amyloidosis-pipeline-review-1
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218